(City)

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

(State)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

| OMB APPROVAL | | | | | | | | |
|--------------------------|-----|--|--|--|--|--|--|--|
| OMB Number: 3235-0287 | | | | | | | | |
| Estimated average burden | | | | | | | | |
| hours per response: | 0.5 | | | | | | | |

| | | | or Section 30(n) of the investment Company Act of 1940 | | | | |
|---|--|----------------|--|------------------------|--|----------------------|--|
| 1. Name and Addi Nicholson N | | Person* | 2. Issuer Name and Ticker or Trading Symbol Apellis Pharmaceuticals, Inc. [APLS] | | lationship of Reporting Person(s) to Issuer ck all applicable) Director 10% Owner Officer (give title Other (specify | | |
| (Last) (First) (Middle) C/O APELLIS PHARMACEUTICALS, INC. 100 FIFTH AVENUE, 3RD FLOOR (Street) WALTHAM MA 02451 | | EUTICALS, INC. | 3. Date of Earliest Transaction (Month/Day/Year) 01/21/2022 | | Chief Technic | below) al Officer | |
| | | | 4. If Amendment, Date of Original Filed (Month/Day/Year) | 6. Indir Line) X | , | | |

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 2. Transaction 2A. Deemed Execution Date 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 1. Title of Security (Instr. 3) 5. Amount of 6. Ownership 7. Nature Securities Beneficially Owned Following Form: Direct (D) or Indirect of Indirect Beneficial Transaction (Month/Day/Year) Code (Instr. 8) 5) if any (Month/Day/Year) (I) (Instr. 4) Ownership (Instr. 4) Reported (A) or (D) Transaction(s) (Instr. 3 and 4) Price Amount Code 26,051(1) 36,205(2) Common Stock 01/21/2022 Α \$<mark>0</mark> D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---|---|--|---|---|---|--|-----|--|--------------------|---|--|---|--|--|--|
| | | | | Code | v | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | | | |
| Stock Option (Right to Buy) | \$35.46 | 01/21/2022 | | A | | 36,951 | | (3) | 01/20/2032 | Common Stock | 36,951 | \$0 | 36,951 | D | |

Explanation of Responses:

- 1. This represents a restricted stock unit grant made on January 21, 2022 that vests 25% annually in equal installments over four years from the date of grant, subject to continued service.
- 2. This includes 758 shares from 04/30/21 ESPP Purchase and 21 shares from 10/29/21 ESPP Purchase.

(Zip)

3. This represents a non-qualified stock option grant made on January 21, 2022 that vests over a four year period with 25% vesting one year from grant date and the remaining 75% vesting in equal monthly installments thereafter through the fourth anniversary of the grant date, subject to continued service.

> /s/ David Watson, attorney-infact for Nur Nicholson

01/25/2022

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.